Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(3):352–359. doi: 10.1054/bjoc.2000.1620

Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas

J M Arnold 1, S C Mok 2, D Purdie 1, G Chenevix-Trench 1,3
PMCID: PMC2363740  PMID: 11161400

Abstract

The molecular events that drive the initiation and progression of ovarian adenocarcinoma are not well defined. We have investigated changes in gene expression in ovarian cancer cell lines compared to an immortalized human ovarian surface epithelial cell line (HOSE) using a cDNA array. We identified 17 genes that were under-expressed and 10 genes that were over-expressed in the cell lines compared to the HOSE cells. One of the genes under-expressed in the ovarian cancer cell lines, Id3, a transcriptional inactivator, was selected for further investigation. Id3 mRNA was expressed at reduced levels in 6 out of 9 ovarian cancer cell lines compared to the HOSE cells while at the protein level, all 7 ovarian cancer cell lines examined expressed the Id3 protein at greatly reduced levels. Expression of Id3 mRNA was also examined in primary ovarian tumours and was found in only 12/38 (32%) cases. A search was conducted for mutations of Id3 in primary ovarian cancers using single stranded conformation polymorphism (SSCP) analysis. Only one nucleotide substitution, present also in the corresponding constitutional DNA, was found in 94 ovarian tumours. Furthermore no association was found between LOH at 1p36 and lack of expression of Id3. These data suggest that Id3 is not the target of LOH at 1p36. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: ovarian cancer, tumour suppressor gene, Id3, cDNA array, loss of heterozygosity

Full Text

The Full Text of this article is available as a PDF (216.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackwell T. K., Weintraub H. Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. Science. 1990 Nov 23;250(4984):1104–1110. doi: 10.1126/science.2174572. [DOI] [PubMed] [Google Scholar]
  2. Bruening W., Prowse A. H., Schultz D. C., Holgado-Madruga M., Wong A., Godwin A. K. Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res. 1999 Oct 1;59(19):4973–4983. [PubMed] [Google Scholar]
  3. Buick R. N., Pullano R., Trent J. M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 1985 Aug;45(8):3668–3676. [PubMed] [Google Scholar]
  4. Chenevix-Trench G., Leary J., Kerr J., Michel J., Kefford R., Hurst T., Parsons P. G., Friedlander M., Khoo S. K. Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus. Oncogene. 1992 Jun;7(6):1059–1065. [PubMed] [Google Scholar]
  5. Deed R. W., Hirose T., Mitchell E. L., Santibanez-Koref M. F., Norton J. D. Structural organisation and chromosomal mapping of the human Id-3 gene. Gene. 1994 Dec 30;151(1-2):309–314. doi: 10.1016/0378-1119(94)90676-9. [DOI] [PubMed] [Google Scholar]
  6. Foster K. A., Harrington P., Kerr J., Russell P., DiCioccio R. A., Scott I. V., Jacobs I., Chenevix-Trench G., Ponder B. A., Gayther S. A. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res. 1996 Aug 15;56(16):3622–3625. [PubMed] [Google Scholar]
  7. Hamilton T. C., Young R. C., McKoy W. M., Grotzinger K. R., Green J. A., Chu E. W., Whang-Peng J., Rogan A. M., Green W. R., Ozols R. F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983 Nov;43(11):5379–5389. [PubMed] [Google Scholar]
  8. Imyanitov E. N., Birrell G. W., Filippovich I., Sorokina N., Arnold J., Mould M. A., Wright K., Walsh M., Mok S. C., Lavin M. F. Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene. 1999 Aug 12;18(32):4640–4642. doi: 10.1038/sj.onc.1202863. [DOI] [PubMed] [Google Scholar]
  9. Israel M. A., Hernandez M. C., Florio M., Andres-Barquin P. J., Mantani A., Carter J. H., Julin C. M. Id gene expression as a key mediator of tumor cell biology. Cancer Res. 1999 Apr 1;59(7 Suppl):1726s–1730s. [PubMed] [Google Scholar]
  10. Janssen J. W., Schulz A. S., Steenvoorden A. C., Schmidberger M., Strehl S., Ambros P. F., Bartram C. R. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene. 1991 Nov;6(11):2113–2120. [PubMed] [Google Scholar]
  11. Kohler M., Janz I., Wintzer H. O., Wagner E., Bauknecht T. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res. 1989 Nov-Dec;9(6):1537–1547. [PubMed] [Google Scholar]
  12. Kruk P. A., Maines-Bandiera S. L., Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest. 1990 Jul;63(1):132–136. [PubMed] [Google Scholar]
  13. Langdon S. P., Lawrie S. S., Hay F. G., Hawkes M. M., McDonald A., Hayward I. P., Schol D. J., Hilgers J., Leonard R. C., Smyth J. F. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 1988 Nov 1;48(21):6166–6172. [PubMed] [Google Scholar]
  14. Leary J. A., Kerr J., Chenevix-Trench G., Doris C. P., Hurst T., Houghton C. R., Friedlander M. L. Increased expression of the NME1 gene is associated with metastasis in epithelial ovarian cancer. Int J Cancer. 1995 Jun 22;64(3):189–195. doi: 10.1002/ijc.2910640308. [DOI] [PubMed] [Google Scholar]
  15. Lee S. W., Tomasetto C., Sager R. Positive selection of candidate tumor-suppressor genes by subtractive hybridization. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2825–2829. doi: 10.1073/pnas.88.7.2825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Li S., MacLachlan T. K., De Luca A., Claudio P. P., Condorelli G., Giordano A. The cdc-2-related kinase, PISSLRE, is essential for cell growth and acts in G2 phase of the cell cycle. Cancer Res. 1995 Sep 15;55(18):3992–3995. [PubMed] [Google Scholar]
  17. Liang P., Pardee A. B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 1992 Aug 14;257(5072):967–971. doi: 10.1126/science.1354393. [DOI] [PubMed] [Google Scholar]
  18. Lin H., Huber R., Schlessinger D., Morin P. J. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res. 1999 Feb 15;59(4):807–810. [PubMed] [Google Scholar]
  19. Lyden D., Young A. Z., Zagzag D., Yan W., Gerald W., O'Reilly R., Bader B. L., Hynes R. O., Zhuang Y., Manova K. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 1999 Oct 14;401(6754):670–677. doi: 10.1038/44334. [DOI] [PubMed] [Google Scholar]
  20. Mandai M., Konishi I., Kuroda H., Komatsu T., Yamamoto S., Nanbu K., Matsushita K., Fukumoto M., Yamabe H., Mori T. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol. 1998 Jan;29(1):34–40. doi: 10.1016/s0046-8177(98)90387-2. [DOI] [PubMed] [Google Scholar]
  21. Merajver S. D., Pham T. M., Caduff R. F., Chen M., Poy E. L., Cooney K. A., Weber B. L., Collins F. S., Johnston C., Frank T. S. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet. 1995 Apr;9(4):439–443. doi: 10.1038/ng0495-439. [DOI] [PubMed] [Google Scholar]
  22. Mielnicki L. M., Hughes R. G., Chevray P. M., Pruitt S. C. Mutated Atf4 suppresses c-Ha-ras oncogene transcript levels and cellular transformation in NIH3T3 fibroblasts. Biochem Biophys Res Commun. 1996 Nov 12;228(2):586–595. doi: 10.1006/bbrc.1996.1702. [DOI] [PubMed] [Google Scholar]
  23. Mok S. C., Chan W. Y., Wong K. K., Cheung K. K., Lau C. C., Ng S. W., Baldini A., Colitti C. V., Rock C. O., Berkowitz R. S. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene. 1998 May 7;16(18):2381–2387. doi: 10.1038/sj.onc.1201769. [DOI] [PubMed] [Google Scholar]
  24. Mok S. C., Chan W. Y., Wong K. K., Muto M. G., Berkowitz R. S. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene. 1996 May 2;12(9):1895–1901. [PubMed] [Google Scholar]
  25. Murre C., McCaw P. S., Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell. 1989 Mar 10;56(5):777–783. doi: 10.1016/0092-8674(89)90682-x. [DOI] [PubMed] [Google Scholar]
  26. Norton J. D., Atherton G. T. Coupling of cell growth control and apoptosis functions of Id proteins. Mol Cell Biol. 1998 Apr;18(4):2371–2381. doi: 10.1128/mcb.18.4.2371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Norton J. D., Deed R. W., Craggs G., Sablitzky F. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol. 1998 Feb;8(2):58–65. [PubMed] [Google Scholar]
  28. O'Bryan J. P., Frye R. A., Cogswell P. C., Neubauer A., Kitch B., Prokop C., Espinosa R., 3rd, Le Beau M. M., Earp H. S., Liu E. T. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991 Oct;11(10):5016–5031. doi: 10.1128/mcb.11.10.5016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Obata K., Morland S. J., Watson R. H., Hitchcock A., Chenevix-Trench G., Thomas E. J., Campbell I. G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998 May 15;58(10):2095–2097. [PubMed] [Google Scholar]
  30. Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999 Mar 15;80(6):827–841. doi: 10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  31. Piétu G., Alibert O., Guichard V., Lamy B., Bois F., Leroy E., Mariage-Sampson R., Houlgatte R., Soularue P., Auffray C. Novel gene transcripts preferentially expressed in human muscles revealed by quantitative hybridization of a high density cDNA array. Genome Res. 1996 Jun;6(6):492–503. doi: 10.1101/gr.6.6.492. [DOI] [PubMed] [Google Scholar]
  32. Ragnarsson G., Eiriksdottir G., Johannsdottir J. T., Jonasson J. G., Egilsson V., Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer. 1999 Mar;79(9-10):1468–1474. doi: 10.1038/sj.bjc.6690234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ruoslahti E. Integrin signaling and matrix assembly. Tumour Biol. 1996;17(2):117–124. doi: 10.1159/000217975. [DOI] [PubMed] [Google Scholar]
  34. Sager R. Expression genetics in cancer: shifting the focus from DNA to RNA. Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):952–955. doi: 10.1073/pnas.94.3.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Schummer M., Ng W. V., Bumgarner R. E., Nelson P. S., Schummer B., Bednarski D. W., Hassell L., Baldwin R. L., Karlan B. Y., Hood L. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999 Oct 1;238(2):375–385. doi: 10.1016/s0378-1119(99)00342-x. [DOI] [PubMed] [Google Scholar]
  36. Shelling A. N., Cooke I. E., Ganesan T. S. The genetic analysis of ovarian cancer. Br J Cancer. 1995 Sep;72(3):521–527. doi: 10.1038/bjc.1995.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Shih Y. C., Kerr J., Liu J., Hurst T., Khoo S. K., Ward B., Wainwright B., Chenevix-Trench G. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int J Cancer. 1997 Mar 4;70(5):508–511. doi: 10.1002/(sici)1097-0215(19970304)70:5<508::aid-ijc3>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  38. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  39. Tsao S. W., Mok S. C., Fey E. G., Fletcher J. A., Wan T. S., Chew E. C., Muto M. G., Knapp R. C., Berkowitz R. S. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res. 1995 Jun;218(2):499–507. doi: 10.1006/excr.1995.1184. [DOI] [PubMed] [Google Scholar]
  40. Vasmatzis G., Essand M., Brinkmann U., Lee B., Pastan I. Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis. Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):300–304. doi: 10.1073/pnas.95.1.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Velculescu V. E., Zhang L., Vogelstein B., Kinzler K. W. Serial analysis of gene expression. Science. 1995 Oct 20;270(5235):484–487. doi: 10.1126/science.270.5235.484. [DOI] [PubMed] [Google Scholar]
  42. Wang K., Gan L., Jeffery E., Gayle M., Gown A. M., Skelly M., Nelson P. S., Ng W. V., Schummer M., Hood L. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene. 1999 Mar 18;229(1-2):101–108. doi: 10.1016/s0378-1119(99)00035-9. [DOI] [PubMed] [Google Scholar]
  43. Ward B. G., Wallace K., Shepherd J. H., Balkwill F. R. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res. 1987 May 15;47(10):2662–2667. [PubMed] [Google Scholar]
  44. Wilson A. P. Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J Natl Cancer Inst. 1984 Mar;72(3):513–521. [PubMed] [Google Scholar]
  45. Wilson A. P., Ford C. H., Newman C. E., Howell A. cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment. Br J Cancer. 1987 Dec;56(6):763–773. doi: 10.1038/bjc.1987.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wolf C. R., Hayward I. P., Lawrie S. S., Buckton K., McIntyre M. A., Adams D. J., Lewis A. D., Scott A. R., Smyth J. F. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer. 1987 Jun 15;39(6):695–702. doi: 10.1002/ijc.2910390607. [DOI] [PubMed] [Google Scholar]
  47. Wong A. S., Maines-Bandiera S. L., Rosen B., Wheelock M. J., Johnson K. R., Leung P. C., Roskelley C. D., Auersperg N. Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer. 1999 Apr 12;81(2):180–188. doi: 10.1002/(sici)1097-0215(19990412)81:2<180::aid-ijc3>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  48. Woods L. K., Morgan R. T., Quinn L. A., Moore G. E., Semple T. U., Stedman K. E. Comparison of four new cell lines from patients with adenocarcinoma of the ovary. Cancer Res. 1979 Nov;39(11):4449–4459. [PubMed] [Google Scholar]
  49. Wright K., Wilson P., Morland S., Campbell I., Walsh M., Hurst T., Ward B., Cummings M., Chenevix-Trench G. beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer. 1999 Aug 27;82(5):625–629. doi: 10.1002/(sici)1097-0215(19990827)82:5<625::aid-ijc1>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  50. Yasue H., Takeda A., Ishibashi M. Amplification of the c-myc gene and the elevation of its transcripts in human ovarian tumor lines. Cell Struct Funct. 1987 Feb;12(1):121–125. doi: 10.1247/csf.12.121. [DOI] [PubMed] [Google Scholar]
  51. Yu Y., Xu F., Peng H., Fang X., Zhao S., Li Y., Cuevas B., Kuo W. L., Gray J. W., Siciliano M. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214–219. doi: 10.1073/pnas.96.1.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Zhou D. J., Gonzalez-Cadavid N., Ahuja H., Battifora H., Moore G. E., Cline M. J. A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas. Cancer. 1988 Oct 15;62(8):1573–1576. doi: 10.1002/1097-0142(19881015)62:8<1573::aid-cncr2820620819>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES